Journal
FRONTIERS IN PHARMACOLOGY
Volume 4, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2013.00001
Keywords
cystic fibrosis; CFTR; proteostasis regulators; autophagy; BECN1
Categories
Funding
- European Institute for Research in Cystic Fibrosis
- Italian Cystic Fibrosis Association
- Programma di Ricerca Scientifica di Rilevante Interesse Nazionale of the Ministero dell'Istruzione, dell'Universita e della Ricerca [2008RMJB3A_004, RO1 HL093004]
- Telethon Grant [GGP12128]
- Ligue Nationale contre le Cancer (Equipe labellisee)
- AXA Chair for Longevity Research
- Agence Nationale pour la Recherche (ANR)
- European Commission
- Foundation pour la Recherche Medicate (FRM)
- Institute National du Cancer (INCa)
- Canceropole Ile-de-France
- Fondation Bettencourt-Schueller
- LabEx Onco-Immunology
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093004] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Cystic fibrosis (CF) patients harboring the most common deletion mutation of the CF transmembrane conductance regulator (CFTR), F508del, are poor responders to potentiators of CFTR channel activity which can be used to treat a small subset of CF patients who genetically carry plasma membrane (PM)-resident CFTR mutants. The misfolded F508del-CFTR protein is unstable in the PM even if rescued by pharmacological agents that prevent its intracellular retention and degradation. CF is a conformational disease in which defective CFTR induces an impressive derangement of general proteostasis resulting from disabled autophagy. In this review, we discuss how rescuing Beclin 1 (BECN1), a major player of autophagosome formation, either by means of direct gene transfer or indirectly by administration of proteostasis regulators, could stabilize F508del-CFTR at the PM. We focus on the relationship between the improvement of peripheral proteostasis and CFTR PM stability in F508del-CFTR homozygous bronchial epithelia or mouse lungs. Moreover, this article reviews recent pre-clinical evidence indicating that targeting the intracellular environment surrounding the misfolded mutant CFTR instead of protein itself could constitute an attractive therapeutic option to sensitize patients carrying the F508del-CFTR mutation to the beneficial action of CFTR potentiators on lung inflammation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available